참고문헌
- Kishi Y, Okumura F, Furuya H. Haemodynamic effects of nicardipine hydrochloride. Studies during its use to control acute hypertension in anaesthetized patients. Br J Anaesth 1984; 56: 1003-1007. https://doi.org/10.1093/bja/56.9.1003
- Hysing ES, Chelly JE, Doursout MF, et al., Cardiovascular effects of and interaction between calcium blocking drugs and anesthetics in chronically instrumented dogs. Nicardipine and isoflurane. Anaesthesiology 1986; 65: 385-391. https://doi.org/10.1097/00000542-198610000-00007
- Van Swieten PA, Hansson L, Epstein M. Slowly acting calcium antagonists and their merits. Blood Press 1997; 6: 78-90. https://doi.org/10.3109/08037059709061803
- Graham DJ, Dow RJ, Freedman D, et al., Pharmacokinetics of nicardipine following oral and intravenous administration in man. Postgrad Med J 1984; 4: 7-10.
- Graham DJ, Dow RJ, Hall DJ, et al., The metabolism and pharmacokinetics of nicardipine hydrochloride in man. Br J Cli. Pharmacol 1985; 1: 23-28.
- Higuchi S, Shiobara Y. Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro. Xenobiotica 1980: 10, 889-896. https://doi.org/10.3109/00498258009033822
- Guengerich FP. Reactions and significance of cytochrome P- 450 enzymes. J Biol Chem 1991; 266: 10019-10022.
- Guengerich FP, Martin MV, Beaune PH, et al., Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1986; 261: 5051-5060.
- Hu YP, Chapey C, Robert J. Relationship between the inhibition of azidopine binding to P-glycoprotein by MDR modulators and their efficiency in restoring doxorubicin intracellular accumulation. Cancer Lett 1996; 109: 203-209. https://doi.org/10.1016/S0304-3835(96)04454-0
- Wang EJ, Casciano CN, Clement RP, et al., Two transport binding sites of P-glycoprotein are unequal yet contingent: initial rate kinetic analysis by ATP hydrolysis demonstrates intersite dependence. Biochim Biophys Acta 2000; 1481: 63-74. https://doi.org/10.1016/S0167-4838(00)00125-4
- Saltiel E, Ward A. Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutics efficacy in platelet-dependent disease states. Drugs 1987; 34: 222-262. https://doi.org/10.2165/00003495-198734020-00003
- Gent M, Blakely JA, Easton JD, et al., The Canadian American ticlopidine study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215-1220.
- Hass, W. k., Easton, J. D., Adams, H. P., et al., A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501-507. https://doi.org/10.1056/NEJM198908243210804
- Janzon L, Bergqvist D, Boberg J, et al., Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med 1990; 227: 301-308. https://doi.org/10.1111/j.1365-2796.1990.tb00164.x
- Haynes RB, Sandler RS, Larson EB, et al., A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events. Arch Intern Med 1998; 152: 1376- 1380.
- Ito MK, Smith AR, Lee ML. Ticlopidine: a new platelet aggregation inhibitors. Clin Pharm 1992; 11: 603-617.
- Verhaeghe R. Prophylactic antiplatelet therapy in peripheral arterial disease. Drugs 1991; 42: 51-57.
- Solomon DH, Hart RG. Antithrombotic therapies for stroke prevention. Curr Opin Neuro 1994; 7: 48-53. https://doi.org/10.1097/00019052-199402000-00009
- Buur T, Larsson R, Berglund U, et al., Pharmocokinetics and effect of ticlopidine on platelet aggregation in subjects with normal and impaired renal function. J Clin Pharmacol 1997; 37: 108-115. https://doi.org/10.1002/j.1552-4604.1997.tb04768.x
- Ko JW, Desta Z, Soukhova NV, et al., In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C9 and CYP2D6. Br J Clin Pharmacol 2000; 49: 343-351.
- Gidal BE, Sorkness CA, McGill KA, et al., Evaluation of a potential enantioselective interaction between ticlopidine and warfarin in chronically anticoagulated patients. Ther Drug Monit 1995; 17: 33-38. https://doi.org/10.1097/00007691-199502000-00006
- Shah J, Fratis A, Ellis D, et al., Effect of food and antacid on absorption of orally administered ticlopidine hydrochloride. J Clin Pharmacol 1990; 30: 733-736. https://doi.org/10.1002/j.1552-4604.1990.tb03635.x
- Eastwood RJ, Galustian C, Bhamra RK, et al., Highperformance liquid chromatographic method for the measurement of nicardipine in plasma or serum. J Chromatogr 1990; 530: 463-468. https://doi.org/10.1016/S0378-4347(00)82351-8
- Kaminsky LS, Fasco MJ. Small intestinal cytochromes P450. Crit Rev Toxicol 1991; 21: 407-422 .
- Cummins CL, Jacobsen W, Benet LZ. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002; 300: 1036-1045. https://doi.org/10.1124/jpet.300.3.1036
- Benet LZ, Cummins CL, Wu CY. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab 2003; 4: 393-398. https://doi.org/10.2174/1389200033489389
- Saeki T, Ueda K, Tanigawara Y, et al., P-glycoproteinmediated transcellular transport of MDR-reversing agents. FEBS Lett 1993; 324: 99-102. https://doi.org/10.1016/0014-5793(93)81540-G
- Wacher VJ, Salphati L, Benet LZ. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 2001; 46: 89-102. https://doi.org/10.1016/S0169-409X(00)00126-5
- Kolars JC, Schmiedlin-Ren P, Schuetz JD, et al., Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992; 90: 1871-1878. https://doi.org/10.1172/JCI116064
- Lea AP, McTavish D. Atorvastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs 1997; 53: 828-847. https://doi.org/10.2165/00003495-199753050-00011
- Holtzman CW, Wiggins BS, Spinler SA. Role of Pglycoprotein in statin drug interaction. Pharmacotherapy 2006; 26: 1601-1607. https://doi.org/10.1592/phco.26.11.1601
- Choi DH, Chang KS, Hong SP, et al., Effect of atorvastatin on intravenous and oral pharmacokinetics of verapamil in rats. Biopharm Drug Dispos 2008; 29: 45-50 https://doi.org/10.1002/bdd.582